MedTrace Logo

Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate

NCT00919022 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 194

Last updated 2012-11-01

No results posted yet for this study

Summary

Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable carcinoma of the prostate.

Sexual functions remain very important in men with prostate cancer. However sexual functions are deteriorating fast with course of the disease. The influence of CPA on sexual functions remains controversial. IIEF-5 erectile dysfunction questionnaire is currently widely used validated simple scoring system for diagnosing of erectile dysfunction and belongs to most used systems in Czech Republic. At present there are no data on CPA influence on IIEF-5 scored erectile dysfunction within the use of its indication in prostate cancer.

Conditions

Interventions

DRUG

Cyproterone Acetate (Androcur, BAY94-8367)

Patients in regular clinical practice receiving Androcur according to local drug information

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Completion
2011-08-31

Countries

  • Czechia

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00919022 on ClinicalTrials.gov